{
    "nct_id": "NCT05998447",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2023-08-21",
    "study_start_date": "2023-09-18",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: GEN-001"
            },
            {
                "drug_name": "Drug: mFOLFOX"
            },
            {
                "drug_name": "Drug: Pembrolizumab"
            }
        ]
    },
    "long_title": "A Phase II Study to Evaluate the Safety and the Efficacy of GEN-001 in Combination With Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer",
    "last_updated": "2024-03-21",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE2",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Genome & Company",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 148,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* The patient (or legally acceptable representative if applicable) provides written informed consent for the trial.",
        "* Be \u226519 years of age on day of signing informed consent.",
        "* Patient with histologically or cytologically confirmed diagnosis of unresectable, recurrent, or metastatic advanced biliary tract adenocarcinoma of the gallbladder or biliary tree (either intrahepatic or extrahepatic cholangiocarcinoma)",
        "Exclude - Exclusion Criteria:",
        "Exclude - * A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",
        "Exclude - * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (Cohort 1 only), and was discontinued from the previous IO therapy due to a Grade 3 or higher immune-related AE (irAE) (Cohort 2 and Cohort 3).",
        "Exclude - * Is currently participating and receiving study treatments or has participated in a study of an investigational agent and received the study therapy or has used an investigational device within 4 weeks prior to the first dose of study treatment.",
        "Exclude - * Has had an allogeneic tissue/solid organ transplan"
    ],
    "short_title": "GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Genome & Company",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "This is a phase II, multicenter, open-label study with a safety run-in to evaluate the safety and efficacy of GEN-001 in combination with pembrolizumab or in combination with pembrolizumab and mFOLFOX for patients with advanced refractory BTC who have progressed after 1 or 2 prior standard therapy and are not candidates for any other standard therapy. The safety run-in phase will be conducted before the main study phase",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "GEN-001 with pembrolizumab or GEN-001 with pembrolizumab and mFOLFOX",
                        "arm_internal_id": 0,
                        "arm_description": "Drug: GEN-001\n\nDrug: pembrolizumab\n\nDrug: mFOLFOX",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: GEN-001",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Pembrolizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: mFOLFOX",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "or": [
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Intraductal Papillary Neoplasm of the Bile Duct"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Intracholecystic Papillary Neoplasm"
                                        }
                                    }
                                ]
                            },
                            {
                                "clinical": {
                                    "age_numerical": ">=19",
                                    "disease_status": [
                                        "Unresectable",
                                        "Recurrent",
                                        "Metastatic",
                                        "Advanced"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        ]
    }
}